Company Profile

Recipharm AB (publ) is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). The Company's acivities are devided into four business segments: Advanced Delivery Systems, which develops and manufactures inhalation products and devices including integrated drug solutions, medical check valves and injection devices. Steriles, which manufactures sterile products, including the use of lyophilisation and blow-fillseal (BFS) technologies. Solids & Others, which manufactures non-sterile products, including tablets, capsules, semi-solids, liquids and powders but excluding inhalation products and Development & Licensing, which provides pharmaceutical development services, and manages Recipharm's patents, technologies, and drug product rights, as well as the development and manufacturing of drug substance (Active Pharmaceutical Ingredient, API). The Company operates worldwide.

Employees

Sector

Pharmaceuticals

More about the company

02-17	Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB.	CI
11-20	Infant Bacterial Therapeutics AB Secures Partnership with Recipharm Advanced Bio for Production of Drug Substance	CI

02-17	Scinai Immunotherapeutics Ltd. acquired Recipharm Israel Ltd. from Recipharm AB.	CI
11-20	Infant Bacterial Therapeutics AB Secures Partnership with Recipharm Advanced Bio for Production of Drug Substance	CI
30/09/25	Recipharm AB Appoints Rodolfo J. Savitzky as Chief Financial Officer, Effective October 1, 2025	CI
14/03/25	Recipharm AB Reports Revenue Results for the Full Year 2024	CI
27/02/25	Recipharm Announces the Opening of Its New Pilot Scale Development Centre in Germany	CI
22/01/25	Spektus Pharma and Recipharm Announce Strategic Partnership to Develop and Supply CNS Medicines Using Flexitab Oral Drug Delivery Platform	CI
24/09/24	Blue Wolf Capital Partners LLC completed the acquisition of Seven manufacturing and development facilities of Recipharm AB.	CI
01/04/24	Blue Wolf Capital Partners LLC agreed to acquire Seven manufacturing and development facilities of Recipharm AB.	CI
27/11/23	Synokem Pharmaceuticals Limited acquired 74% stake in Nitin Lifesciences Limited from Recipharm AB.	CI
22/11/23	Recipharm Announces CEO Changes	CI
22/11/23	Recipharm Appoints Marc Funk as Board of Directors	CI
23/08/23	Recipharm Announces Executive Appointments	CI
10/05/23	NewBiologix SA announced that it has received CHF 45 million in funding from Recipharm AB and other investors	CI

11/04/24	Åsa Bergström New COO at Nanologica AB (publ)	AQ
03/04/24	Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm	AQ
27/03/24	Recipharm attains major sustainability milestones	AQ
24/01/24	Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology	AQ
12/12/23	ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas LNP formulations	AQ

08/02/21	Samsung Biologics : Eurazeo prépare une vente du groupe pharmaceutique Seqens, selon des sources
28/01/21	EN DIRECT DES MARCHES : STMicroelectronics, Elior, TechnipFMC, Valneva, Apple, Tesla, BMW, EasyJet...
11/01/21	Avis d'analystes du jour : Air Liquide, Airbus, Aperam, Fresenius, LafargeHolcim, Saint-Gobain, Straumann...
11/01/21	La bourse reste hermétique au déclin de Trump
14/12/20	EN DIRECT DES MARCHES : Vivendi, Danone, Solutions 30, Vallourec, Gaussin, Alexion, Codemasters, Oracle, Ferrari

Manager	Title	Age	Since
Grégory Behar CEO	Chief Executive Officer	57	31/12/2023
Joaquim Beneyto Mascaro DFI	Director of Finance/CFO	-	02/04/2023
Luc Burgard COO	Chief Operating Officer	46	-

Recipharm publ AB Share Price Swiss Exchange

Stocks

SE0005757267

Pharmaceuticals

Latest news: Recipharm publ AB

Press Releases: Recipharm publ AB

News in other languages: Recipharm publ AB

Managers and Directors: Recipharm publ AB

Specialty & Advanced Pharmaceuticals

Company Profile

Director	Title	Age	Since
Richard Ridinger CHM	Chairman	68	28/02/2021
Mark Burgess Keatley BRD	Director/Board Member	69	31/12/2020
Erika Karin Elisabeth Henriksson BRD	Director/Board Member	45	28/02/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+2.70%	+2.73%	+40.91%	+110.31%	1,032B
JOHNSON & JOHNSON	+1.44%	-2.38%	+36.83%	+63.95%	614B
ABBVIE INC.	+1.75%	+3.73%	+16.55%	+83.05%	471B
MERCK & CO., INC.	+0.60%	-1.73%	+62.98%	+37.46%	350B
ROCHE HOLDING AG	+2.92%	+3.12%	+24.78%	+45.10%	337B
NOVARTIS AG	+2.42%	+0.05%	+14.13%	+35.80%	268B
ASTRAZENECA PLC	+1.86%	-0.81%	-4.69%	+12.20%	246B
AMGEN INC.	+2.60%	-2.00%	+39.77%	+54.44%	218B
GILEAD SCIENCES, INC.	+1.82%	-1.48%	+25.75%	+96.48%	179B
Average	+1.46%	-1.16%	+28.56%	+59.87%	412.76B
Weighted average by Cap.	+0.81%	-0.47%	+32.01%	+70.59%

End-of-day quote Swiss Exchange
- ^SEK	-